MEVACOR MONOTHERAPY COULD BRING 85% OF PATIENTS' LDL LEVELS DOWN TO NCEP GOALS, MERCK MAINTAINS; COMPANY OUTLINES DEFENSE AGAINST SANDOZ' LESCOL
Executive Summary
Merck estimates that 85% of patients treated with the maximum dose of Mevacor will achieve LDL cholesterol lowering sufficient to meet the goals set by the National Cholesterol Education Program.